Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors
- Written by ACN Newswire - Press Releases
Read more //?#
.
Retailers combat post-Christmas debt and boost revenue amid changing customer behaviours
As the festive season wraps up, Australian retailers and companies are shifting their focus from holiday sales to addressing the challenges of pos...
When Will Infrastructure Companies See Gains from Generative AI?
A lot of questions are swirling about the state of generative AI right now. How far along are companies with their bespoke GenAI efforts? Are orga...
DLPA partners with Crestcom to bring its leadership training solutions
Dynamic Leadership Programs Australia (DLPA), a leading provider of leadership training and workforce strategy solutions, has joined forces with r...
Infosys and Tennis Australia Create New Generative AI Innovations at the Australian Open 2025
Infosys (NSE, BSE, NYSE: INFY), a global leader in next-generation digital services and consulting, in partnership with Tennis Australia, has unv...
UBH Group Pioneers Australia's Path to Nuclear Sovereignty
Sovereign technology company, UBH Group, has achieved a landmark milestone as the first organisation in the Southern Hemisphere to secure ISO 1944...
The unsung heroes: How MSPs can safeguard SMBs while boosting profitability
In Australia, small-to-medium-sized businesses (SMBs) form the backbone of the economy, accounting for 95% of all businesses. Yet, they remain pri...
